Semaglutide/Glycine/B12

• Helps address appetite and supports management of cravings
• Supports metabolic wellness and weight management^2-4
• Supports healthy A1C levels (a marker of blood sugar control)
• Aids in cardiometabolic health measures
• Supports insulin sensitivity^1-3

• The medication is not insulin.
• Dose adjustments should aim for the lowest appropriate dose to limit unwanted effects and improve adherence.
• Possible side effects such as nausea, constipation, acid reflux, stomach pain, vomiting, diarrhea, and injection site reactions are common.

• Contraindicated in patients with a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia Syndromes (MEN 2)
• Not suitable for individuals with type 1 diabetes or diabetic ketoacidosis
• Should not be used alongside other GLP-1 receptor medications
• Gastric emptying may be delayed, requiring caution for procedures involving sedation or general anesthesia due to aspiration risk
• Use caution in those with a history of diabetic retinopathy^1-3
• Consult your healthcare provider if you have a history of pancreatitis, as the medication may increase risk
• Serious side effects may involve hypoglycemia, kidney issues, or allergic reactions
• Avoid use during pregnancy and breastfeeding¹

Handling Requirements

• Keep away from children and pets

• Supports glucose-dependent insulin secretion
• Helps downregulate glucagon secretion
• Helps slow gastric emptying
• Influences brain regions involved in appetite regulation, helping to address hunger and caloric intake
• Supports insulin sensitivity^1-3
• Supports weight management goals
• Helps support a healthy response to internal inflammation and assist with metabolic wellness and healthy cardiovascular function⁵

Q: How long does it take to see a potential outcome? 

A: Individual responses vary, but literature suggests that observations related to hunger signals or weight management goals may be noted within weeks. Timing depends on patient physiology, medication adherence, and other individual factors.

Q: Can I use this with other medications? 

A: It can be used with certain medications, but it should not be used in combination with other GLP-1 medications. Always inform your healthcare provider about all medications and supplements you're taking to address possible interactions.

Q: Why is it formulated with glycine and vitamin B12?

A: Cyanocobalamin (vitamin B12) and glycine are added to the formulation to complement patient care plans regarding possible side effect management and muscle support.

Q: What if I miss an injection? 

A: Contact your healthcare provider for guidance on missed doses.

IMPORTANT INFORMATION ABOUT COMPOUNDED MEDICATIONS

This medication has been compounded (custom-prepared) by a pharmacy. Compounded medications are specially prepared for identified individual patient needs based on a valid prescription from a prescribing healthcare practitioner and, as such, are not reviewed or approved by the U.S. Food and Drug Administration (FDA) for safety or efficacy. Compounded drugs are intended for patients whose prescriber has determined their medical needs are not met by an available FDA-approved drug. These statements have not been evaluated by the FDA.

This compounded preparation:

• Has not been approved by the FDA
• Has not undergone FDA review for safety, effectiveness, or quality
• Is prepared specifically for you based on your prescriber's order
• Individual outcomes may vary

Dosing is determined by the prescribing provider based on patient-specific factors. Always follow your healthcare provider's instructions. Compounded medications are not subject to FDA approval and lack the same safety and efficacy data as FDA-approved commercial medications. This medication should be prescribed and monitored by a licensed healthcare professional familiar with the condition being addressed and the specific applications of the medication.

1. Lexicomp Online. Semaglutide: Drug information. Lexi-Drugs database. Wolters Kluwer. Accessed May 14, 2025. https://online.lexi.com/lco/action/ doc/retrieve/docid/patch_f/6577162

2. Chao AM, Tronieri JS, Amaro A, Wadden TA. Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations. Drug Des Devel Ther. 2022 Dec 29;16:4449-4461. doi: 10.2147/DDDT.S365416. PMID: 36601368; PMCID: PMC9807016.

3. Khoo TK, Lin J. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Jul 1;385(1):e4. doi: 10.1056/NEJMc2106918. PMID: 34192447.

4. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11. PMID: 37952131.